Gene Editing Market

Analysis from GMI Research finds that the Gene Editing Market earned revenues of USD 3.1 billion in 2021 and estimated to touch USD 9.0 billion in 2029 will grow at a high double-digit CAGR of 14.3% from 2022-2029.

To have an edge over the competition by knowing the market dynamics and current trends of “Gene Editing Market,” request for Sample Report here

Key Drivers

Growing awareness about stem cell therapies and rising private funding are the major factors fueling the gene editing market growth. The ongoing technological innovations in gene-editing tools will strengthen the market growth. For instance, in April 2021, researchers from Wyss Institute for Biologically Inspired Engineering at Harvard launched Retron Library Recombineering (RLR) – a new gene-editing tool to enhance the performance of millions of genetic experiments simultaneously, thus offering better editing rates. Increasing inclination for personalized medicine, rising Research & Development expenditure and expansion of biotechnology and pharmaceutical industries, ongoing innovations in sequencing and Genome Editing technologies, and rising use of products derived from genetically modified organisms are some factors propelling the growth of the genome editing market.

Moreover, rising private and public partnership and technological innovations like Clustered Regularly Interspace Short Palindromic Repeats (CRISPR/Cas9) are projected to expand the market growth. As per the cellular biochemistry, the CRISPR-Cas9 technique is an important technology for targeted genome editing within many diverse organisms including bacteria, yeast, zebrafish, mosquitoes, mouse, and mammals. However, moral issues associated with the use of gene editing among people might hinder the gene editing market growth over the forecast period.

Do you want to know more about the Research process and detailed Methodology, Request Research Methodology of this report

Technology Segment Analysis

CRISPR/Cas9 is expected to lead the gene editing market over the forecast period, due to the remarkable advantages including recovery in a guide RNA-specific manner, targeted gene disruption, and regulation across various applications. Increase in the number of ongoing clinical trials using gene-editing techniques to treat diseases like cancer, AIDS, and genetic diseases along with the growing adoption of CRISPR in culture and animal breeding applications will further add to the market. Moreover, the CRISPR technology is user-friendly, simple, and cost-effective as compared to other techniques, which is another reason boosting the demand. Growing use of CRISPR technology in the biopharmaceutical industry to improve the productivity of CHO cell lines to produce large molecule therapeutics has stimulated the segment’s growth.

End-User Segment Analysis

Pharma-Biotech companies are expected to witness a higher CAGR over the upcoming years, due to the increasing emphasis on developing new gene editing technologies by several biotechnology companies. Rising research activities and collaboration of pharmaceutical companies for the development of advanced therapeutic is expected to catalyze the segment’s share. For example, Horizon Discovery is emphasizing on the generation of genome editing tool with advanced technology for accurate and efficient functional genes.

Application Segment Analysis

Cell line engineering application is forecast to witness a higher CAGR over the forecast period, due to its increasing use for stem cell based-cell therapy treatment. Ongoing advancements in editing techniques like Zinc Finger Nucleases (ZFNs), CRISPR/Cas, and TALENs have eased the cell engineering processes, which is estimated to pave the way for segment.

In case, any of your pain points areas are not covered in the current scope of this report, Request for Customization here

Regional Analysis

North American gene editing market is estimated to hold a higher share over the forecast period, due to the growing expenditure in research and expansion of pharmaceuticals and biotechnology industries. Increasing incidences of rare diseases in the U.S. and Canada have driven the gene editing market growth. As per the National Institutes of Health (NIH), the cases of 7,000 rare diseases impacted between 25 and 30 million Americans. Therefore, the demand for development of drugs to cure rare diseases increases by adaption of new gene editing tools and technologies. The presence of research, advanced therapy development and increasing number of clinical trials for gene and stem cell therapies will strengthen the market growth.

Top Market Players

Major players operating in the market are CRISPR Therapeutics, Sangamo Therapeutics, Editas Medicine, Intellia Therapeutics, Cellectis. Other notable players are Agilent Technologies, Allele Biotech, Bio Rad, Thermo Fisher Scientific, DNA Technologies.

Key Developments:

• • In 2021, Caribou Biosciences, Inc. entered into an agreement with AbbVie for the research and development of CAR-T therapy. Under this agreement, Abbvie was offered the rights to use Caribou’s CRISPR genome editing technology.
  • IN 2020, Takara Bio licensed CRISPR genome editing technology from Merck KGaA (Millipore Sigma) to enhance Takara’s stem cell service capabilities including the development of vectors.

Segments covered in the Report:

The Global Gene Editing Market has been segmented based on technology, application, end user and key geographies. Based on technology, the market comprises of Cluster Regularly Interspaced Short Palindromic Repeats (CRISPR), Transcription Activator-Like Effector Nucleases (TALEN), Zing Finger Nucleases (ZFN), Others. The research report “Global Editing Market” provides in-depth analysis Global Editing Market based on raw material, composition, form, application and major geographies for the forecast period from 2018 to 2025. The report also highlights the major market drivers propelling the growth as well as challenges faced by market participants. The research report provides market size and forecast for the Global Editing Market. In addition, the report also analyses the competitive landscape, major players and their strategies in 2018. The competitive landscape section of the report captures and highlights the recent developments in the market.

Key questions answered in this research report:

• • At what pace Global Editing Market is growing? What will be growth trend in future?
  • What are the key drivers and restraints in the current market? What will be the impact of drivers and restraints in the future?
  • What are the regional revenue and forecast breakdowns? Which are the major regional revenue pockets for growth in the Global Editing Market?
  • What are the various type, source, application areas and how they are poised to grow?

Report Coverage	Details
Market Revenues (2021)	USD 3.1 billion
Market Base Year	2021
Market Forecast Period	2022-2029
Base Year & Forecast Units	Revenues (USD Million)
Market Segment	By Technology, By Application, By End-User, By Region
Regional Coverage	Asia Pacific, Europe, North America, and RoW
Companies Profiled	CRISPR Therapeutics, Sangamo Therapeutics, Editas Medicine, Intellia Therapeutics, Cellectis. Other notable players are Agilent Technologies, Allele Biotech, Bio Rad, Thermo Fisher Scientific, DNA Technologies, among others; a total of 10 companies covered.
25% Free Customization Available	We will customize this report up to 25% as a free customization to address our client’s specific requirements

Market Segmentation

Global Gene Editing Market by Technology

• Cluster Regularly Interspaced Short Palindromic Repeats (CRISPR)
• Transcription Activator-Like Effector Nucleases (TALEN)
• Zing FingerNucleases (ZFN)
• Others

Global Gene Editing Market by Application

• Animal Genetic Engineering
• Therapeutic Application
• Genetically Modified Organisms
• Plant Genetic Engineering
• Cell Line Engineering

Global Gene Editing Market by End-User

• Pharma-BioTech Companies
• Academic Institutes & Research Center
• Agrigenomic Companies
• Contract Research Organization

Global Gene Editing Market by Region

• • North America Global Gene Editing Market (Option 1: As a part of the free 25% customization)
    • By Technology
    • By Application
    • By End-User
    • US Market All-Up
    • Canada Market All-Up
  • Europe Global Gene Editing Market (Option 2: As a part of the free 25% customization)
    • By Technology
    • By Application
    • By End-User
    • UK Market All-Up
    • Germany Market All-Up
    • France Market All-Up
    • Spain Market All-Up
    • Rest of Europe Market All-Up
  • Asia-Pacific Global Gene Editing Market (Option 3: As a part of the free 25% customization)
    • By Technology
    • By Application
    • By End-User
    • China Market All-Up
    • India Market All-Up
    • Japan Market All-Up
    • Rest of APAC Market All-Up
  • RoW Global Gene Editing Market (Option 4: As a part of the free 25% customization)
    • By Technology
    • By Application
    • By End-User
    • Brazil Market All-Up
    • South Africa Market All-Up
    • Saudi Arabia Market All-Up
    • UAE Market All-Up
    • Rest of world (remaining countries of the LAMEA region) Market All-Up

Global Gene Editing Market Players (Option 5: As a part of the Free 25% Customization – Profiles of 5 Additional Companies of your Choice)

• • CRISPR Therapeutics
  • Sangamo Therapeutics
  • Editas Medicine
  • Intellia Therapeutic
  • Cellectis

Other notable players

• • Agilent Technologies
  • Allele Biotech
  • Bio Rad
  • Thermo Fisher Scientific
  • DNA Technologies